Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery

Oral rivaroxaban has shown to be superior to subcutaneous enoxaparin in preventing venous thromboembolism (VTE) in patients undergoing non-major orthopaedic surgery with a period of immobilisation [1,2]. No significant difference was observed in major bleeding with rivaroxaban versus enoxaparin. Prof. Nadia Rosencher (Paris Center University Hospital, France) and colleagues in the PRONOMOS trial aimed to compare the effect of rivaroxaban with that of enoxaparin in preventing major VTE during immobilisation after lower-limb non-major orthopaedic surgery [1]. The trial enrolled 3,604 adult patients who underwent non-major orthopaedic surgery of the lower limbs and who required thromboprophylaxis for >2 weeks (investigator’s assessment). The primary efficacy endpoint of the study was major VTE, a composite of symptomatic distal or proximal deep-vein thr...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 7 September, 20209 December, 2020